A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
- 30 March 2007
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 60 (4) , 489-494
Abstract
While gemcitabine (GEM) is widely accepted for the treatment of advanced pancreatic cancer, capecitabine (CAP) has shown single agent activity and promising efficacy in combination with GEM. This phase II study was conducted to evaluate the efficacy and toxicity of GEM combined with dose escalated 14-day CAP as first-line chemotherapy for advanced pancreatic cancer. In addition, we also analyzed the correlation between CA19-9 response and clinical outcomes.Keywords
This publication has 19 references indexed in Scilit:
- PS11 Best of ECCO 13 Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancerEuropean Journal of Cancer Supplements, 2005
- CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trialsBritish Journal of Cancer, 2005
- Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancerBritish Journal of Cancer, 2005
- Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)British Journal of Cancer, 2005
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III TrialJournal of Clinical Oncology, 2005
- The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2005
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004
- Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinomaCancer, 2002
- Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic CancerJournal of Clinical Oncology, 2002
- Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreasGastroenterology, 1986